期刊
ONCOIMMUNOLOGY
卷 11, 期 1, 页码 -出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/2162402X.2021.2017162
关键词
Immune checkpoint inhibitor; immune-related adverse event; latency; predictive marker
资金
- Cancer Prevention and Research Institute of Texas Award [RP200549]
- National Cancer Institute Midcareer Investigator Award in Patient-Oriented Research [K24 CA201543-01]
- National Institute of Allergy and Infectious Disease [1U01AI156189-01]
- American Cancer Society-Melanoma Research Alliance Team Award [MRAT-18-114-01-LIB]
- V Foundation Robin Roberts Cancer Survivorship Award [DT2019-007]
- University of Texas Lung Cancer Specialized Program of Research Excellence (SPORE) [P50CA070907-21]
The timing of immune-related adverse events (irAE) associated with immune checkpoint inhibitors (ICI) varies greatly. Late-onset irAE is associated with better clinical outcomes compared to early-onset irAE.
The timing of immune-related adverse events (irAE) associated with immune checkpoint inhibitors (ICI) is highly variable. Although the development of irAE has been associated with ICI clinical benefit, how irAE timing influences this association is unknown. We analyzed two independent cohorts including 154 patients with non-small cell lung cancer (NSCLC) treated with PD-1/PD-L1 inhibitors at a single institution (UTSW cohort) and a multi-center cohort of 433 patients with NSCLC who received second-line anti-PD-1/PD-L1 therapy (Global cohort) to assess the association between ICI outcomes and irAE timing. In both cohorts, late-onset irAE occurring more than 3 months after ICI initiation compared to irAE occurring earlier were associated with greater rates of radiographic response (UTSW cohort, 41% versus 28%, P = .26; Global cohort, 60% versus 35%, P = .02), longer progression-free (UTSW cohort, 13.7 versus 5.6 months, P < .01; Global cohort, not reached versus 6.0 months, P < .01) and overall survival (UTSW cohort, 30.9 versus 14.6 months, P < .01; Global cohort, not reached versus 10.6 months, P < .01). Modified landmark analysis at 6 months confirmed an overall survival difference between early- and late-onset irAE. Late-onset irAE was similarly associated with greater response rates and prolonged survival in a cohort of 130 patients with non-NSCLC malignancies, suggesting a conserved association across tumor types. The favorable association between irAE and ICI clinical outcomes may be attributed to later-onset events, which is not wholly explained by survivor bias. These results allude to a distinct biology between early- and late-onset irAE and may guide clinician expectations and thresholds for continuing or modifying immunotherapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据